Patents Assigned to FIBROSTATIN, S.L.
  • GPBP inhibition using Q2 peptidomimetics
    Publication number: 20140080852
    Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.
    Type: Application
    Filed: October 25, 2013
    Publication date: March 20, 2014
    Applicant: FIBROSTATIN, S.L.
    Inventors: Juan Saus, Santos Fustero, Juan F Sanz-Cervera, Enrique Pérez-Payá, Raül Blasco, Francisco Revert-Ros, Fernando Revert
  • GPBP inhibition using Qpeptidomimetics
    Patent number: 8586776
    Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: November 19, 2013
    Assignee: FibroStatin, S.L.
    Inventors: Juan Saus, Santos Fustero, Juan F. Sanz-Cervera, Enrique Perez-Paya, Raul Blasco, Francisco Revert-Ros, Fernando Revert
  • Methods for treating and diagnosing disease
    Publication number: 20120213800
    Abstract: The present invention provides methods for the diagnosis and/or treatment of chronic kidney disease, immune complex-mediated GN, rheumatoid arthritis, and pulmonary fibrosis, and methods for identifying compounds for such therapeutic use.
    Type: Application
    Filed: February 21, 2012
    Publication date: August 23, 2012
    Applicant: Fibrostatin S.L.
    Inventors: Juan Saus, Fernando Revert, Ramón Merino, Jesús Merino, Francisco Revert-Ros
  • GPBP inhibition using Q2 peptidomimetics
    Publication number: 20110105545
    Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.
    Type: Application
    Filed: November 5, 2010
    Publication date: May 5, 2011
    Applicant: FIBROSTATIN, S.L.
    Inventors: JUAN SAUS, SANTOS FUSTERO, JUAN F. SANZ-CERVERA, ENRIQUE PEREZ-PAYA, RAUL BLASCO, FRANCISCO REVERT-ROS, FERNANDO REVERT